Skip to main content

Shin Nippon Biomedical Laboratories, Ltd. (2395.T)

Japan Exchange Group Healthcare Medical - Diagnostics & ResearchView data quality →
53.7Fair

ValueMarkers Composite Index

Top 46%#24,170 of 44,714
Undervalued

72% below intrinsic value ($36)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.80
Low Risk
Altman
1.53
Distress
DCF Value
$36
Undervalued
ROIC
1.8%
Low
P/E
15.7
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Shin Nippon Biomedical Laboratories, Ltd. (2395.T) — VMCI valuation read

Headline read on 2395.T: VMCI of 54/100 versus a Healthcare sector median of 50. The 4-point above-median position is what makes Shin Nippon Biomedical Laboratories, Ltd. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 2395.T: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 2395.T: value (2395.T trades at 23.0x earnings, 28% above the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -2.2x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

2395.T fell 2.7% over the trailing 7 days, with a -16.7% read on a 30-day basis.

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

CEO: Ryoichi Nagata1,457 employeesJPwww.snbl.co.jp

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 2395.T’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.